In latest setback for solid tumor CAR-T, Celyad pauses trial following two patient deaths
Efforts to push CAR-T therapy, so effective in many blood cancers, into solid tumors took another hit Monday, after Celyad Oncology announced that two patients had died in a trial for its lead candidate for colorectal cancer.
Celyad said it had “voluntarily” paused the trial as it investigates the deaths, although such voluntary actions often come immediately before the FDA or EMA orders studies halted.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.